Clinical trial
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth…
NCT00233519 · University of Rochester, Other · Completed
Key facts
| NCT number | NCT00233519 |
|---|---|
| Title | Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) |
| Official title | Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) |
| Lead sponsor | University of Rochester, Other |
| Collaborators | National Institute of Neurological Disorders and Stroke (NINDS) NIH Imsmed Incorporated Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myotonic Dystrophy |
| Intervention type | Drug |
| Interventions | SomatoKine/IPLEX |
| Enrollment | 17 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Oct 5, 2005 |
| Last update posted | Jun 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: